<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): March 11, 2009</B>

<P align="center"><IMG src="c82407c8240701.jpg" alt="(LOGO)">

<DIV align="center" style="font-size: 24pt"><B>POLYMEDIX, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>
</DIV>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>000-51895</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>27-0125925</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>170 N. Radnor Chester Road, Suite 300<BR>Radnor, Pennsylvania<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>19087</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(448) 598-2400</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>Not Applicable<BR></B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Item 7.01.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="3"><B>Regulation FD Disclosure.</B></TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">On March&nbsp;11, 2009, PolyMedix, Inc. (the &#147;Company&#148;) issued a press release
announcing Phase IA clinical data for the Company&#146;s heptagonist compound,
PMX-60056. The press release is attached as Exhibit&nbsp;99.1 to this Current
Report on Form&nbsp;8-K.<BR>
&nbsp;<BR>
In accordance with General Instruction B.2 of Form&nbsp;8-K, the information in
this Current Report on Form&nbsp;8-K, including Exhibit&nbsp;99.1, shall not be
deemed &#147;filed&#148; for the purposes of Section&nbsp;18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as shall be expressly
set forth by specific reference in such a filing. The information in this
Report will not be deemed as an admission as to the materiality of any
information required to be disclosed solely to satisfy the requirements of
Regulation&nbsp;FD.</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD nowrap valign="top" align="left"><B>Item&nbsp;9.01(d)</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top"><B>Financial Statements and Exhibits.</B></TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top">99.1 &nbsp;&nbsp;&nbsp;Press release issued March&nbsp;11, 2009 by PolyMedix, Inc.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 10pt"><B>Forward-Looking Statements</B>


<P align="left" style="font-size: 10pt"><I>The press release attached to this Current Report on </I><I>Form 8-K</I><I> as Exhibit&nbsp;99.1 contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and
that could cause PolyMedix&#146;s actual results and experience to differ materially from anticipated results and
expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these
forward-looking statements by using words such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;hopes,&#148; &#147;estimates,&#148; &#147;looks,&#148; &#147;expects,&#148;
&#147;plans,&#148; &#147;intends&#148;, &#147;goal&#148;, &#147;potential,&#148; &#147;may,&#148; &#148;suggest,&#148; and similar expressions. Among other things, there can be
no assurance that PolyMedix&#146;s compounds will enter or successfully complete clinical testing or be granted regulatory
approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks,
uncertainties and assumptions is described under the heading &#147;Risk Factors&#148; in PolyMedix&#146;s filings with the Securities
and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes
no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made
to reflect events or circumstances after the date of this Current Report or to reflect the occurrence of unanticipated
events, except as required by applicable law or regulation.</I>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="center" style="font-size: 10pt"><B>SIGNATURE</B>



<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="55%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POLYMEDIX, INC.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">March&nbsp;11, 2009
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Edward F. Smith</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Edward F. Smith</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" nowrap valign="top">Vice President, Finance and Chief Financial Officer</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P align="center" style="font-size: 10pt"><U><B>Exhibit&nbsp;Index</B></U>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release issued March&nbsp;11, 2009 by PolyMedix, Inc.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt">&nbsp;




</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c82407e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 11867}]
{"company-data": {"conformed-name": "POLYMEDIX INC", "cik": "0001341843", "assigned-sic": "2834", "irs-number": "000000000", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51895", "film-number": "09671331"}, "business-address": {"street1": "C/O POLYMEDIX INC", "street2": "3701 MARKET STREET STE 442", "city": "PHILADELPHIA", "state": "PA", "zip": "19104", "phone": "2159666199"}, "mail-address": {"street1": "C/O POLYMEDIX INC", "street2": "3701 MARKET STREET STE 442", "city": "PHILADELPHIA", "state": "PA", "zip": "19104"}, "former-company": {"former-conformed-name": "BTHC II ACQUISITION CORP", "date-changed": "20051019"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 11, 2009
POLYMEDIX, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-51895
27-0125925
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
170 N. Radnor Chester Road, Suite 300
Radnor, Pennsylvania
19087
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
(448) 598-2400
Not Applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01.
Regulation FD Disclosure.
On March 11, 2009, PolyMedix, Inc. (the "Company") issued a press release
announcing Phase IA clinical data for the Company's heptagonist compound,
PMX-60056. The press release is attached as Exhibit 99.1 to this Current
Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in
this Current Report on Form 8-K, including Exhibit 99.1, shall not be
deemed "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as shall be expressly
set forth by specific reference in such a filing. The information in this
Report will not be deemed as an admission as to the materiality of any
information required to be disclosed solely to satisfy the requirements of
Regulation FD.
Item 9.01(d)
Financial Statements and Exhibits.
99.1    Press release issued March 11, 2009 by PolyMedix, Inc.
Forward-Looking Statements
The press release attached to this Current Report on
Form 8-K
as Exhibit 99.1 contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and
that could cause PolyMedix's actual results and experience to differ materially from anticipated results and
expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these
forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects,"
"plans," "intends", "goal", "potential," "may," "suggest," and similar expressions. Among other things, there can be
no assurance that PolyMedix's compounds will enter or successfully complete clinical testing or be granted regulatory
approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks,
uncertainties and assumptions is described under the heading "Risk Factors" in PolyMedix's filings with the Securities
and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes
no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made
to reflect events or circumstances after the date of this Current Report or to reflect the occurrence of unanticipated
events, except as required by applicable law or regulation.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
POLYMEDIX, INC.
March 11, 2009
/s/ Edward F. Smith
Edward F. Smith
Vice President, Finance and Chief Financial Officer
Exhibit Index
Exhibit No.
99.1
Press release issued March 11, 2009 by PolyMedix, Inc.